Founder · Inventor · Executive Committee
Moacyr Bighetti
The patent is the origin story
Founder of PHP Biotech. Inventor on the company’s bioactive-peptide PCT family, with more than nine patents filed across 40+ countries and product licenses to Bayer Healthcare and Sanofi.
PCT publication
WO2023220553
Bioactive peptides, compositions, production process, and use of bioactive peptides as anti-tumor agents
Bighetti MR, Bezerra PHA · WO2023220553A2 (PCT/US2023/066685); applicant PHP Biotech International Inc.
Read on Google Patents- patents
- 9+
- countries with filings
- 40+
- countries with Bayer or Sanofi licenses
- 20+
Kaivo first, then a US company
The science did not start as a slide deck in Texas. It started as an entrepreneur’s bet on biological products at Kaivo Biotech in Brazil, then crossed into a US corporation with a nanobody plan, a PCT family, and a named scientific lead. Bighetti is the continuity between those two rooms.
WO2023220553 is not a metaphor
The PCT, filed as PCT/US2023/066685 and published as WO2023220553A2, names Moacyr Ramos Bighetti and Patrícia Heloise Alves Bezerra as inventors and PHP Biotech International Inc. as applicant. It covers bioactive snake-venom peptides intended for aggressive solid tumors. That is the legal spine under 3-NAntC.
From Kaivo to PHP
Kaivo
Chief Executive Officer
Kaivo Biotech — biological products, human and veterinary
Licensing
Product licenses
Bayer Healthcare and Sanofi, 20+ countries
2020
Founder
PHP Biotech International Inc.
2023
Lead inventor
WO2023220553 — bioactive anti-tumor peptides
From Kaivo to a US nanobody company
Moacyr Bighetti is the founder of PHP Biotech and a member of its Executive Committee. He is a pharmaceutical R&D entrepreneur with a roughly 20-year track record of translating laboratory innovation into protected, licensable, globally deployed products.
Bighetti is the CEO of Kaivo Biotech, a Brazilian developer of biological products for human and veterinary health. He is credited with more than nine patents, several filed across more than 40 countries, and with licensing products to companies including Bayer Healthcare and Sanofi across more than 20 countries.
As founder, he provides continuity of scientific and strategic vision, bridging the origin of the science at Kaivo Biotech with PHP Biotech’s forward development of PHP53-nb and the GEN01-AD platform. He is a named inventor, with Dr. Patrícia Bezerra, on PCT publication WO2023220553.
Verifiable record
A ledger, not a brochure
Everything below is meant to be checked. Empty categories are omitted rather than padded.
| Record | Detail |
|---|---|
| Affiliation | PHP Biotech International Inc. (Founder; Executive Committee) |
| Affiliation | Kaivo Biotech (Chief Executive Officer) |
| Credential | Founder, PHP Biotech International Inc. |
| Credential | CEO, Kaivo Biotech |
| Credential | 9+ patents; filings in 40+ countries |
| Credential | Product licenses to Bayer Healthcare and Sanofi (20+ countries) |
Expertise
- Pharmaceutical intellectual property
- Venom-derived peptide therapeutics
- International licensing
- Platform company formation
Patents
Indexed on PubMed, Crossref, or Google Patents. Internal, unpublished data is not listed as peer-reviewed work.
Patent · 2023
Bioactive peptides, compositions, production process, and use of bioactive peptides as anti-tumor agents
Bighetti MR, Bezerra PHA
WO2023220553A2 (PCT/US2023/066685); applicant PHP Biotech International Inc.
Lead inventor. Priority family covering bioactive snake-venom peptides for aggressive solid tumors.